4D Molecular Therapeutics (FDMT) Liabilities and Shareholders Equity (2019 - 2026)

4D Molecular Therapeutics (FDMT) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $512.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 0.55% year-over-year to $512.9 million; the TTM figure through Mar 2026 stood at $2.0 billion (down 14.04% YoY), while the FY2025 annual figure was $566.7 million, up 1.13% from the prior year.
• Liabilities and Shareholders Equity eased to $512.9 million in Q1 2026 per FDMT's latest filing, from $566.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $629.9 million in Q1 2024 and bottomed at $244.0 million in Q1 2023.
• Historically, Liabilities and Shareholders Equity has averaged $433.8 million across 5 years, with a median of $424.0 million in 2025.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity soared 158.13% — and 2025, when it dropped 29.81%.
• 4D Molecular Therapeutics' Liabilities and Shareholders Equity stood at $261.8 million in 2022, then grew by 29.81% to $339.9 million in 2023, then jumped by 64.87% to $560.4 million in 2024, then advanced by 1.13% to $566.7 million in 2025, then declined by 9.49% to $512.9 million in 2026.
• Business Quant data shows FDMT's Liabilities and Shareholders Equity at $512.9 million in Q1 2026, $566.7 million in Q4 2025, and $424.0 million in Q3 2025.